Curis (CRIS) Net Equity Issued and Repurchased (2011 - 2026)
Curis' (CRIS) quarterly Net Equity Issued and Repurchased came in at $18.9 million in Q1 2026, up 89.41% YoY from $10.0 million in Q1 2025, and up 16016.81% on a QoQ basis from -$119000.0 in Q4 2025.
Curis (CRIS) Net Equity Issued and Repurchased (2011 - 2026) Analysis & Trends
Curis (CRIS) has 12 years of Net Equity Issued and Repurchased data on file, last reported at $18.9 million in Q1 2026.
- Quarterly Net Equity Issued and Repurchased rose 89.41% year-over-year to $18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.3 million (up 10.24% YoY) and the FY2025 annual result came in at $15.4 million, up 27.69% from the prior year.
- Net Equity Issued and Repurchased improved to $18.9 million in Q1 2026, from -$119000.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $18.9 million in Q1 2026 to a low of -$578000.0 in Q2 2025.
- A 5-year average of $4.8 million and a median of $500000.0 in 2024 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased jumped 9252.54% — and 2025, when it plunged 389.0%.
- Tracing CRIS's Net Equity Issued and Repurchased over 5 years: stood at $179000.0 in 2022, then slumped by 34.08% to $118000.0 in 2023, then jumped by 9252.54% to $11.0 million in 2024, then slumped by 101.08% to -$119000.0 in 2025, then jumped by 16016.81% to $18.9 million in 2026.
- The last three Net Equity Issued and Repurchased figures came in at $18.9 million (Q1 2026), -$119000.0 (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Curis | 3.27 Mn | -2.35 Mn | - | -282,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.94 Mn |
| Mar 31, 2026 | 18.94 Mn |
| Dec 31, 2025 | -119,000.00 |
| Dec 31, 2025 | -119,000.00 |
| Sep 30, 2025 | 6.05 Mn |
| Sep 30, 2025 | 6.05 Mn |
| Jun 30, 2025 | -578,000.00 |
| Jun 30, 2025 | -578,000.00 |
| Mar 31, 2025 | 10.00 Mn |
| Mar 31, 2025 | 10.00 Mn |
| Dec 31, 2024 | 11.04 Mn |
| Dec 31, 2024 | 11.04 Mn |
| Sep 30, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Dec 31, 2023 | 118,000.00 |
| Dec 31, 2023 | 118,000.00 |
| Sep 30, 2023 | 13.81 Mn |
| Sep 30, 2023 | 13.81 Mn |